[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT1633767T - Métodos e composições para controlar a eficácia do silenciamento de arn - Google Patents

Métodos e composições para controlar a eficácia do silenciamento de arn

Info

Publication number
PT1633767T
PT1633767T PT04753864T PT04753864T PT1633767T PT 1633767 T PT1633767 T PT 1633767T PT 04753864 T PT04753864 T PT 04753864T PT 04753864 T PT04753864 T PT 04753864T PT 1633767 T PT1633767 T PT 1633767T
Authority
PT
Portugal
Prior art keywords
compositions
methods
rna silencing
controlling efficacy
efficacy
Prior art date
Application number
PT04753864T
Other languages
English (en)
Inventor
D Zamore Phillip
Tang Guiliang
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of PT1633767T publication Critical patent/PT1633767T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT04753864T 2003-06-02 2004-06-02 Métodos e composições para controlar a eficácia do silenciamento de arn PT1633767T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47538603P 2003-06-02 2003-06-02

Publications (1)

Publication Number Publication Date
PT1633767T true PT1633767T (pt) 2019-02-27

Family

ID=33551539

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04753864T PT1633767T (pt) 2003-06-02 2004-06-02 Métodos e composições para controlar a eficácia do silenciamento de arn

Country Status (9)

Country Link
US (7) US7459547B2 (pt)
EP (2) EP3502252B1 (pt)
AU (1) AU2004248136B2 (pt)
CA (1) CA2528012C (pt)
DK (1) DK1633767T3 (pt)
ES (1) ES2712695T3 (pt)
PL (1) PL1633767T3 (pt)
PT (1) PT1633767T (pt)
WO (1) WO2004111191A2 (pt)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140676D1 (de) 2000-03-30 2010-01-14 Massachusetts Inst Technology Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064625A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
SI1504126T1 (sl) 2002-05-03 2014-08-29 Duke University Office Of Science And Technology Postopek regulacije izraĹľanja genov
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
US7892793B2 (en) 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
PT2284266E (pt) 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
AU2003298718A1 (en) * 2002-11-22 2004-06-18 University Of Massachusetts Modulation of hiv replication by rna interference
AU2004252442B2 (en) * 2003-06-02 2010-04-08 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of FNAi
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
PT1633767T (pt) * 2003-06-02 2019-02-27 Univ Massachusetts Métodos e composições para controlar a eficácia do silenciamento de arn
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
ES2808561T3 (es) 2003-09-12 2021-03-01 Univ Massachusetts Interferencia por ARN para el tratamiento de trastornos de ganancia de función
AU2004280634A1 (en) 2003-10-09 2005-04-21 E. I. Du Pont De Nemours And Company Gene silencing by using micro-RNA molecules
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
US20050273868A1 (en) * 2004-02-17 2005-12-08 University Of Massachusetts Methods and compositions for enhancing RISC activity in vitro and in vivo
WO2005079533A2 (en) * 2004-02-17 2005-09-01 University Of Massachusetts Methods and compositions for mediating gene silencing
EP2322650A1 (en) 2004-05-14 2011-05-18 Rosetta Genomics Ltd MicroRNAs and uses thereof
US7795419B2 (en) 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
EP2290076B1 (en) 2004-05-28 2015-03-25 Asuragen, Inc. Methods and compositions involving microRNA
KR101409241B1 (ko) 2004-09-28 2014-06-24 쿠아크 파마수티칼스 인코퍼레이티드 탈모증, 급성신부전증 및 다른 질환의 치료를 위한 올리고리보뉴클레오티드 및 그것의 사용방법
WO2006044322A2 (en) * 2004-10-12 2006-04-27 The Rockefeller University Micrornas
CA2857901A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
US20060200878A1 (en) 2004-12-21 2006-09-07 Linda Lutfiyya Recombinant DNA constructs and methods for controlling gene expression
WO2006073727A2 (en) 2004-12-21 2006-07-13 Monsanto Technology, Llc Recombinant dna constructs and methods for controlling gene expression
CN101611142A (zh) * 2005-07-07 2009-12-23 综合医院公司 用于控制干细胞分化的方法
AU2006279280A1 (en) 2005-08-18 2007-02-22 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating neurological disease
WO2007073149A1 (en) * 2005-12-22 2007-06-28 Keygene N.V. Alternative nucleotides for improved targeted nucleotide exchange
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
EP1989307B1 (en) * 2006-02-08 2012-08-08 Quark Pharmaceuticals, Inc. NOVEL TANDEM siRNAS
JP5635772B2 (ja) 2006-08-01 2014-12-03 ジェン−プロウブ インコーポレイテッド 核酸の非特異的標的の捕捉方法
EP2076599A2 (en) * 2006-09-19 2009-07-08 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
EP3199646A1 (en) 2006-10-12 2017-08-02 Monsanto Technology LLC Plant micrornas and methods of use thereof
EP2097525B1 (en) * 2006-12-21 2013-06-19 Novozymes Inc. Methods of reducing or eliminating expression of genes in filamentous fungal strains by transitive rna interference
WO2008091680A2 (en) * 2007-01-25 2008-07-31 The General Hospital Corporation Methods for controlling stem cell differentiation
WO2008104978A2 (en) * 2007-02-28 2008-09-04 Quark Pharmaceuticals, Inc. Novel sirna structures
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
US20080313773A1 (en) * 2007-05-14 2008-12-18 The Rockefeller University Production of artificial micrornas using synthetic microrna precursors
WO2008147824A2 (en) 2007-05-22 2008-12-04 Mdrna, Inc. Hydroxymethyl substituted rna oligonucleotides and rna complexes
PT2170403E (pt) 2007-06-27 2014-07-17 Quark Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes pró-apoptóticos
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20100280097A1 (en) * 2007-09-18 2010-11-04 Intradigm Corporation Compositions comprising hif-1 alpha sirna and methods of use thereof
JP2010538678A (ja) * 2007-09-18 2010-12-16 イントラドイグム コーポレーション Ｋ−ｒａｓｓｉＲＮＡ含有組成物及びそれらの使用法
DK2548962T3 (en) 2007-09-19 2016-04-11 Applied Biosystems Llc Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof
WO2009044392A2 (en) * 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US8071562B2 (en) 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
MX2010006169A (es) * 2007-12-04 2010-06-23 Univ Ohio State Res Found Enfoques moleculares para la optimizacion de la produccion de biocombustibles.
US20090181438A1 (en) * 2007-12-04 2009-07-16 The Ohio State University Research Foundation Optimization of biofuel production
US20110105584A1 (en) * 2007-12-12 2011-05-05 Elena Feinstein Rtp80il sirna compounds and methods of use thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
WO2009086428A2 (en) * 2007-12-28 2009-07-09 The Regents Of The University Of California Methods and compositions for increasing gene expression
EP2242854A4 (en) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc COMPOUNDS AND USES THEREOF
EP2250265A1 (en) * 2008-03-12 2010-11-17 Intradigm Corporation Compositions comprising notch1 sirna and methods of use thereof
KR20100132531A (ko) * 2008-03-20 2010-12-17 쿠아크 파마수티칼스 인코퍼레이티드 ＲＴＰ801을 억제하기 위한 신규 ｓｉＲＮＡ 화합물
EP2285385A4 (en) * 2008-04-15 2013-01-16 Quark Pharmaceuticals Inc COMPOUNDS BASED ON RNSI TO INHIBIT NRF2
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2009147684A2 (en) 2008-06-06 2009-12-10 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
WO2010008562A2 (en) 2008-07-16 2010-01-21 Recombinetics Methods and materials for producing transgenic animals
AU2009322290B2 (en) 2008-12-03 2016-06-16 Arcturus Therapeutics, Inc. Una oligomer structures for therapeutic agents
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
CN102803496A (zh) 2009-06-10 2012-11-28 淡马锡生命科学研究院有限公司 用于棉花中基因功能性分析的病毒诱导的基因沉默(vigs)
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
US20110097329A1 (en) 2009-06-26 2011-04-28 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
WO2011057171A1 (en) 2009-11-08 2011-05-12 Quark Pharmaceuticals, Inc. METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM
CA2776568A1 (en) 2009-11-26 2011-06-03 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
WO2011088435A1 (en) 2010-01-15 2011-07-21 Cornell University Methods for reducing protein levels in a cell
MX2012010479A (es) 2010-03-08 2012-10-09 Monsanto Technology Llc Moleculas polinucleotidicas para regulacion genetica en plantas.
CA2794307A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
EP2561075B1 (en) 2010-04-23 2018-06-27 University of Massachusetts Aav-based treatment of cholesterol-related disorders
JP5963743B2 (ja) 2010-04-23 2016-08-03 ユニバーシティ オブ マサチューセッツ Ｃｎｓターゲティングａａｖベクターおよびその使用方法
CA2833905C (en) 2010-04-23 2019-09-10 University Of Massachusetts Multicistronic expression constructs
US20130324591A1 (en) 2010-12-06 2013-12-05 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
US9226976B2 (en) 2011-04-21 2016-01-05 University Of Massachusetts RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
AR088155A1 (es) 2011-09-13 2014-05-14 Monsanto Technology Llc Metodos y composiciones para el control de malezas
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
UA115535C2 (uk) 2011-09-13 2017-11-27 Монсанто Текнолоджи Ллс Спосіб та композиція для боротьби з бур'янами (варіанти)
CN110066794A (zh) 2011-09-13 2019-07-30 孟山都技术公司 用于杂草控制的方法和组合物
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
EP3382027A3 (en) 2011-09-13 2018-10-31 Monsanto Technology LLC Methods and compositions for weed control
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
UY34822A (es) 2012-05-24 2013-12-31 Seeds Ltd Ab Composiciones y métodos para silenciar la expresión genética
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
BR112015008706A2 (pt) 2012-10-18 2018-02-06 Monsanto Technology Llc métodos e composições para controle de praga de plantas
WO2014106838A2 (en) 2013-01-01 2014-07-10 A.B. Seeds Ltd. Methods of introducing dsrna to plant seeds for modulating gene expression
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
UA121846C2 (uk) 2013-03-13 2020-08-10 Монсанто Текнолоджи Ллс Спосіб та гербіцидна композиція для контролю видів рослини роду lolium
CA2905027A1 (en) 2013-03-13 2014-10-09 Monsanto Technology Llc Methods and compositions for weed control
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
WO2014181344A2 (en) * 2013-04-08 2014-11-13 Munisekhar Medasani Bioactive apolar extract containing plant genetic material for treatment of mammalian diseases
MX359191B (es) 2013-07-19 2018-09-18 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US20160208247A1 (en) 2013-07-31 2016-07-21 Qbi Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
WO2015015496A1 (en) 2013-07-31 2015-02-05 Qbi Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
WO2015066681A1 (en) 2013-11-04 2015-05-07 Monsanto Technology Llc Compositions and methods for controlling arthropod parasite and pest infestations
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
WO2015108982A2 (en) 2014-01-15 2015-07-23 Monsanto Technology Llc Methods and compositions for weed control using epsps polynucleotides
US10072251B2 (en) 2014-02-19 2018-09-11 University Of Massachusetts Recombinant AAVS having useful transcytosis properties
EP4410805A3 (en) 2014-03-18 2024-11-27 University of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
EP3122365B1 (en) 2014-03-25 2023-05-03 Arcturus Therapeutics, Inc. Transthyretin allele selective una oligomers for gene silencing
US9856475B2 (en) 2014-03-25 2018-01-02 Arcturus Therapeutics, Inc. Formulations for treating amyloidosis
WO2015148580A2 (en) 2014-03-25 2015-10-01 Arcturus Therapeutics, Inc. Una oligomers having reduced off-target effects in gene silencing
CN110506752B (zh) 2014-04-01 2022-02-18 孟山都技术公司 用于控制虫害的组合物和方法
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
CA2953347A1 (en) 2014-06-23 2015-12-30 Monsanto Technology Llc Compositions and methods for regulating gene expression via rna interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
RU2754955C2 (ru) 2014-07-29 2021-09-08 Монсанто Текнолоджи Ллс Композиции и способы борьбы с насекомыми-вредителями
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2016086142A1 (en) 2014-11-25 2016-06-02 University Of Florida Research Foundation, Inc. Methods and compositions for preventing or reducing infections of crop plants by bacterial and fungal pathogens
WO2016118762A1 (en) 2015-01-22 2016-07-28 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
US10584321B2 (en) 2015-02-13 2020-03-10 University Of Massachusetts Compositions and methods for transient delivery of nucleases
EP3277289A4 (en) 2015-04-01 2018-12-05 Arcturus Therapeutics, Inc. Therapeutic una oligomers and uses thereof
EP3277815B1 (en) 2015-04-03 2021-09-22 University of Massachusetts Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
ES2808750T3 (es) 2015-04-03 2021-03-01 Univ Massachusetts Compuestos oligonucleotídicos dirigidos a ARNm de huntingtina
WO2016172008A1 (en) 2015-04-24 2016-10-27 University Of Massachusetts Modified aav constructions and uses thereof
EP3302053B1 (en) 2015-06-02 2021-03-17 Monsanto Technology LLC Compositions and methods for delivery of a polynucleotide into a plant
EP3302030A4 (en) 2015-06-03 2019-04-24 Monsanto Technology LLC METHODS AND COMPOSITIONS FOR THE INTRODUCTION OF NUCLEIC ACIDS IN PLANTS
WO2017015671A1 (en) 2015-07-23 2017-01-26 Arcturus Therapeutics, Inc. Compositions for treating amyloidosis
US10633653B2 (en) 2015-08-14 2020-04-28 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
AU2016332821B2 (en) 2015-09-28 2022-02-17 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
US11299537B2 (en) 2015-12-10 2022-04-12 Fibrogen, Inc. Methods for treatment of motor neuron diseases
EP3408391A4 (en) 2016-01-31 2019-08-28 University of Massachusetts BRANCHED OLIGONUCLEOTIDES
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
CN109414414A (zh) 2016-03-16 2019-03-01 戴维·格拉德斯通研究所 用于治疗肥胖症和/或糖尿病以及用于鉴定候选治疗剂的方法和组合物
MA45469A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques de bêta-caténine et leurs utilisations
MA45470A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques kras et leurs utilisations
MA45349A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Acides nucléiques egfr et leurs utilisations
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
EP3496758A4 (en) 2016-08-12 2020-11-11 University of Massachusetts CONJUGATE OLIGONUCLEOTIDES
UA126801C2 (uk) 2016-08-17 2023-02-08 Монсанто Текнолоджі Ллс Конструкція рекомбінантної днк для спільної супресії генів ендогенної оксидази
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
CN110506119A (zh) 2016-10-13 2019-11-26 马萨诸塞大学 Aav衣壳设计
EP3529261A4 (en) 2016-10-19 2020-04-15 Monsanto Technology LLC COMPOSITIONS AND METHODS FOR MODIFYING FLOWERING AND PLANT ARCHITECTURE TO IMPROVE YIELD POTENTIAL
US10443055B2 (en) 2016-12-22 2019-10-15 Beth Israel Deaconess Medical Center Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
WO2018208972A1 (en) 2017-05-09 2018-11-15 University Of Massachusetts Methods of treating amyotrophic lateral sclerosis (als)
CN110799647A (zh) 2017-06-23 2020-02-14 马萨诸塞大学 双尾自递送sirna及相关的方法
CA3075643A1 (en) 2017-09-22 2019-03-28 University Of Massachusetts Sod1 dual expression vectors and uses thereof
WO2019079240A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
MA51103A (fr) 2017-12-06 2020-10-14 Avidity Biosciences Inc Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
UY38095A (es) 2018-02-15 2019-10-01 Monsanto Technology Llc Composiciones y métodos para mejorar los rendimientos de cultivos mediante el apilamiento de rasgos
CA3094465A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
SG11202009451VA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
MX2021001590A (es) 2018-08-10 2021-07-02 Univ Massachusetts Oligonucleótidos modificados dirigidos a snp.
US11492619B2 (en) 2019-01-18 2022-11-08 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
EP3966328A4 (en) 2019-05-06 2023-10-18 University Of Massachusetts Anti-c9orf72 oligonucleotides and related methods
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
US11212555B2 (en) 2019-06-19 2021-12-28 Tencent America LLC Method of reducing context models for entropy coding of transform coefficient significant flag
AU2020329155A1 (en) 2019-08-09 2022-03-10 University Of Massachusetts Chemically modified oligonucleotides targeting SNPs
BR112022006530A2 (pt) 2019-10-17 2022-07-05 Stridebio Inc Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c
US12037585B2 (en) 2019-12-23 2024-07-16 University Of Massachusetts Oligonucleotides for tissue specific gene expression modulation
KR20220156867A (ko) 2020-03-19 2022-11-28 어비디티 바이오사이언시스 인크. 안면견갑상완 근이영양증의 치료용 조성물 및 방법
EP4126070A4 (en) 2020-03-26 2024-07-24 University Of Massachusetts Synthesis of modified oligonucleotides with increased stability
WO2021243291A2 (en) 2020-05-28 2021-12-02 University Of Massachusetts Oligonucleotides for sars-cov-2 modulation
US12104163B2 (en) 2020-08-19 2024-10-01 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
CN117677699A (zh) 2021-06-23 2024-03-08 马萨诸塞大学 用于治疗先兆子痫和其他血管生成病症的优化抗flt1寡核苷酸化合物
WO2024259134A1 (en) 2023-06-13 2024-12-19 Arnatar Therapeutics, Inc Advanced rna targeting (arnatar) for angiotensinogen

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0228458B2 (en) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
US5252726A (en) 1987-09-04 1993-10-12 Novo Nordisk A/S Promoters for use in aspergillus
EP0633318A1 (en) 1987-09-11 1995-01-11 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
WO1989005345A1 (en) 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
EP0400047B1 (en) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5070020A (en) 1988-05-09 1991-12-03 Eli Lilly And Company Recombinant dna expression vectors and dna compounds that encode deacetoxycephalosporin c synthetase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
WO1991006309A1 (en) 1989-11-03 1991-05-16 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US6946587B1 (en) 1990-01-22 2005-09-20 Dekalb Genetics Corporation Method for preparing fertile transgenic corn plants
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
JP3418982B2 (ja) 1990-10-31 2003-06-23 ソマティクス セラピー コーポレイション 内皮細胞の遺伝的変性
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
ES2150832B1 (es) 1996-06-12 2001-06-16 Fichtel & Sachs Ag Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion.
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20040002153A1 (en) * 1999-07-21 2004-01-01 Monia Brett P. Modulation of PTEN expression via oligomeric compounds
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE60140676D1 (de) * 2000-03-30 2010-01-14 Massachusetts Inst Technology Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind
US20020173478A1 (en) * 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
WO2003035869A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
KR20040022449A (ko) * 2001-07-12 2004-03-12 유니버시티 오브 매사추세츠 유전자 불활성화를 매개하는 소형 간섭 ｒｎａ의 생체내제조
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
EP2428569B1 (en) * 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
WO2003068797A1 (en) * 2002-02-14 2003-08-21 City Of Hope Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
SI1504126T1 (sl) * 2002-05-03 2014-08-29 Duke University Office Of Science And Technology Postopek regulacije izraĹľanja genov
CA2489174C (en) * 2002-07-10 2013-02-05 Thomas Tuschl Rna-interference by single-stranded rna molecules
US7184819B2 (en) * 2002-08-01 2007-02-27 Draeger Medical Systems, Inc. User interface system for use in ECG signal derivation and management
DK1389637T3 (da) 2002-08-05 2012-09-03 Silence Therapeutics Ag Interfererende RNA-molekyler med stumpe ender
EP3222725A1 (en) 2002-08-05 2017-09-27 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
WO2004014933A1 (en) * 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
AU2003273336A1 (en) * 2002-09-18 2004-04-08 Isis Pharmaceuticals, Inc. Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
WO2004029212A2 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
AU2003290586B2 (en) * 2002-11-04 2009-07-02 University Of Massachusetts Allele-specific RNA interference
US7892793B2 (en) * 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
PT2284266E (pt) * 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
US20040214198A1 (en) * 2002-11-15 2004-10-28 University Of Massachusetts Allele-targeted RNA interference
US20040248299A1 (en) 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
US20040224328A1 (en) * 2003-01-15 2004-11-11 Hans Prydz siRNA screening method
WO2004063375A1 (en) 2003-01-15 2004-07-29 Hans Prydz OPTIMIZING siRNA BY RNAi ANTISENSE
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
EP2314687B1 (en) * 2003-01-17 2017-12-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inducible small interfering rna (sirna) expression constructs for targeted gene silencing
US20070104688A1 (en) * 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
DK2216407T3 (en) 2003-03-07 2016-03-29 Alnylam Pharmaceuticals Inc therapeutic compositions
PT1633767T (pt) * 2003-06-02 2019-02-27 Univ Massachusetts Métodos e composições para controlar a eficácia do silenciamento de arn
AU2004252442B2 (en) 2003-06-02 2010-04-08 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of FNAi
US7750144B2 (en) * 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
CA2546669C (en) * 2003-11-26 2021-08-03 University Of Massachusetts Sequence-specific inhibition of small rna function
WO2005062937A2 (en) 2003-12-22 2005-07-14 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
US20060134787A1 (en) * 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
WO2005069987A2 (en) 2004-01-23 2005-08-04 City Of Hope Amplifying interfering rna (rnai) expression and effects
US20050256072A1 (en) * 2004-02-09 2005-11-17 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
US20050273868A1 (en) * 2004-02-17 2005-12-08 University Of Massachusetts Methods and compositions for enhancing RISC activity in vitro and in vivo
WO2005079533A2 (en) 2004-02-17 2005-09-01 University Of Massachusetts Methods and compositions for mediating gene silencing
JP2005247605A (ja) * 2004-03-02 2005-09-15 Ngk Insulators Ltd セラミック多孔質体及びその製造方法
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20070265220A1 (en) * 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US20060178334A1 (en) * 2005-02-04 2006-08-10 City Of Hope Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon

Also Published As

Publication number Publication date
CA2528012A1 (en) 2004-12-23
US7459547B2 (en) 2008-12-02
US20080318896A1 (en) 2008-12-25
US11459562B2 (en) 2022-10-04
PL1633767T3 (pl) 2019-07-31
US10364429B2 (en) 2019-07-30
AU2004248136B2 (en) 2011-09-15
AU2004248136A1 (en) 2004-12-23
EP1633767A4 (en) 2007-04-11
EP3502252A1 (en) 2019-06-26
ES2712695T3 (es) 2019-05-14
DK1633767T3 (en) 2019-03-25
US20050037988A1 (en) 2005-02-17
US7772203B2 (en) 2010-08-10
US20200032261A1 (en) 2020-01-30
EP1633767B1 (en) 2018-11-21
US20100317105A1 (en) 2010-12-16
EP3502252B1 (en) 2023-04-05
CA2528012C (en) 2015-11-24
US20110152347A1 (en) 2011-06-23
US20140163084A1 (en) 2014-06-12
WO2004111191A3 (en) 2005-12-22
EP1633767A2 (en) 2006-03-15
WO2004111191A2 (en) 2004-12-23
US20090098614A1 (en) 2009-04-16
US7732593B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
PT1633767T (pt) Métodos e composições para controlar a eficácia do silenciamento de arn
AU2003257013A1 (en) Methods and compositions for amplification of dna
AU2003279010A8 (en) Compositions and methods for delivery of short interfering rna and short hairpin rna
HK1089086A1 (en) Compositions and methods for controlling insects
EP1696910A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS
AU2003261449A1 (en) Compositions for rna interference and methods of use thereof
HK1091840A1 (en) Methods and compositions for therapeutic use of rna interference
IL174627A0 (en) Compositions and methods for treatment of burns
GB0325192D0 (en) Method of use
PL1696721T3 (pl) Transgeny tłumienia genu dominującego i sposoby ich zastosowania
EP1654379A4 (en) METHOD AND COMPOSITIONS FOR IMPROVED PROTEIN EXPRESSION AND CLEANING
IL219406A0 (en) Antiloading compositions and methods of selecting same
AU2003239129A8 (en) Methods and compositions for dna manipulation
IL174325A0 (en) Dna vaccine compositions and methods of use
GB0608813D0 (en) Improved methods and compositions for RNA interference
EP1628993A4 (en) METHOD AND COMPOSITIONS FOR RNA INTERFERENCE
SG118236A1 (en) Compositions and methods for treating coronavirus infection and SARS
ZA200508646B (en) Compositions and methods for controlling insects
EP1615942A4 (en) Polymerase inhibitor and method for its use
EP1663124A4 (en) ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE
GB0324523D0 (en) Compositions and methods of treatment
GB0322963D0 (en) Methods of controlling reducant addition
EP1653997A4 (en) METHODS AND COMPOSITIONS FOR CONTROLLING ECTOPARASITES
GB0314190D0 (en) Method of controlling weeds
GB0419175D0 (en) Method of treatment and compositions